Allen Ex Rel. Allen v. Bayer Corp.

460 F.3d 1217
CourtCourt of Appeals for the Ninth Circuit
DecidedAugust 29, 2006
Docket04-35370, 04-35562, 04-35588, 04-35611, 04-35614, 04-35621, 04-35884, 04-36137, 05-35105, 05-35121, 05-35129, 05-35147, 05-35184
StatusPublished
Cited by2 cases

This text of 460 F.3d 1217 (Allen Ex Rel. Allen v. Bayer Corp.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Allen Ex Rel. Allen v. Bayer Corp., 460 F.3d 1217 (9th Cir. 2006).

Opinions

RYMER, Circuit Judge.

These appeals are from judgments of dismissal entered in a multidistrict litigation (MDL) proceeding for failure to comply with case management orders. The orders were entered with the agreement of all sides that they were necessary to move hundreds of cases and thousands of plaintiffs toward resolution on the merits. The district court found that many plaintiffs inexcusably failed to do what was required, and dismissed their actions. Some appeal. We must decide whether these dismissals were a clear error of judgment.

The principles that guide a court’s discretion to dismiss are well settled, but we have never addressed how they play out in the context of multidistrict litigation. We conclude that while the rules are the same as for ordinary litigation on an ordinary docket — that is, a court determining whether to dismiss an action on account of a plaintiffs noncompliance with a court order must weigh the public’s interest in expeditious resolution of litigation; the court’s need to manage its docket; the risk of prejudice to the defendants; the public policy favoring the disposition of cases on their merits; and the availability of less drastic sanctions — multidistrict litigation is different because of the large number of cases that must be coordinated, its greater complexity, and the court’s statutory charge to promote the just and efficient conduct of the actions. 28 U.S.C. § 1407. As a result, the considerations that inform the exercise of discretion in multidistrict litigation may be somewhat different, and may tip the balance somewhat differently, from ordinary litigation on an ordinary docket.

Recognizing this, we cannot say that the district court abused its discretion in dismissing the cases before us, except for McGriggs and Sasseen, as to which we reverse.2

I

Phenylopropanolamine (PPA) was used in many decongestants and weight-control products until the Food and Drug Admin[1223]*1223istration (FDA) issued a public health advisory on November 6, 2000 warning that this ingredient potentially increased the risk of hemorrhagic stroke. See U.S. Food & Drug Admin., Ctr. for Drug Evaluation & Research, Pub. Health Advisory Subject: Safety of Phenylpropanolamine, Nov. 6, 2000, http://www.fda.gov/cder/drug/info-page/ppa/ advisory.htm (last visited Feb. 26, 2006). The advisory stated that the FDA was taking steps to remove PPA from drug products and to request drug companies to discontinue marketing products containing PPA. Id.; see also U.S. Food & Drug Admin., Ctr. for Drug Evaluation & Research, Phenylpropanolamine (PPA) Information Page, http:// www.fda.gov/ eder/drug/infopage/ppa/de-fault.htm (last visited Feb. 26, 2006).

As a result, lawsuits were filed in state and federal courts throughout the country against pharmaceutical companies by persons claiming injury for ingestion of a product containing PPA. On motion of plaintiffs in one such action in the Eastern District of Louisiana, the Judicial Panel on Multidistrict Litigation found that fourteen actions then pending in several district courts were rooted in complex core questions concerning the safety of PPA and that centralization was necessary to eliminate duplicative discovery, prevent inconsistent pretrial rulings, and conserve the resources of the parties, their counsel, and the judiciary. See In re Phenylpropanola-mine (PPA) Prods. Liab. Litig. No. 1407, 173 F.Supp.2d 1377, 1379 (J.P.M.L.2001). Accordingly, on August 28, 2001, the Panel designated the Western District of Washington as the appropriate forum for MDL 1407, and ordered the PPA actions to be transferred and assigned to Hon. Barbara Jacobs Rothstein for pretrial consolidation and coordination.3 Id. at 1380.

MDL 1407 got under way with an initial status conference on November 16, 2001. It addressed the leadership structure for counsel, and issues relating to discovery, experts, use of technology, class actions, and federal-state coordination. The court appointed Lead and Liaison Counsel for plaintiffs and defendants on November 21 and a Plaintiffs’ Steering Committee on January 17, 2002. As part of its duties, the Plaintiffs’ Steering Committee was to assist all plaintiffs in MDL 1407 by overseeing discovery, communicating with plaintiffs’ lawyers, making court appearances, attending status conferences, and preparing motions and responses regarding case-wide discovery matters.

At the court’s direction, the parties submitted an agreed-upon Case Management Order (CMO) 1, which-set out basic procedures and a master framework for discovery. Among other things, this order, filed January 29, 2002, states that “[a] party’s failure to either produce a relevant document or identify same as withheld pursuant to a privilege may be viewed by the Court as an infraction of its orders, justifying appropriate sanctions.” CMO 1 at ¶ VIII. It also provides that notice by the court to Plaintiffs’ Liaison Counsel and Defendants’ Liaison Counsel of any matter or ruling relating to all actions would be considered as notice to all MDL 1407 parties, and that service on Liaison Counsel would constitute service on all plaintiffs’ and all defendants’ counsel, respectively. Id. at ¶ III C, D.

A series of eighteen case management orders followed. They were applicable MDL-wide to all PPA actions transferred [1224]*1224to MDL 1407, and governed both MDL-wide and case-specific issues. Case Management Orders were posted on the court’s public website for the PPA litigation (http:// www.wawd.uscourts.gov/mdl). The primary orders at issue in these appeals are CMOs 6, 10, and 19, which control pretrial management of discovery, and CMOs 13 and 15, which concern product identification.

Case Management Order 6, filed March 18, 2002, set forth the basic principles for taking fact discovery of plaintiffs. No objections were lodged to the order in its final form. It requires all case-specific discovery to occur during the time periods permitted in the order, and adopts a “Plaintiffs Fact Sheet” (PFS) protocol in lieu of interrogatories to streamline the process. The PFS is a questionnaire to be signed under oath seeking information about the plaintiffs’ injuries, medical history, current medical condition, identification of the product claimed to have caused injury, specifics of the injury suffered, and the identity of the plaintiffs’ healthcare providers. It also includes blank authorizations to be signed by plaintiffs to allow defendants to collect medical and other records. (CMO 6A replaced several authorizations in CMO 6 that did not comply with federal statutory provisions, but made no other changes.) CMO 6 set a case-specific cutoff date of February 28, 2003 for all cases docketed in the MDL by February 12, 2002, and for cases docketed after February 28, 2003, case-specific discovery was to be completed within 12 months of the docket date. Plaintiffs in every case currently docketed were ordered to complete a Plaintiffs Fact Sheet no later than 45 days after a blank PFS was transmitted by defendants, and plaintiffs in all cases transferred to MDL 1407 thereafter were to complete a PFS within 45 days after service.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
460 F.3d 1217, Counsel Stack Legal Research, https://law.counselstack.com/opinion/allen-ex-rel-allen-v-bayer-corp-ca9-2006.